Kyung Dong Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	31,809	15,769	11,779	14,553	17,807
Short-Term Investments	10,754	10,155	17,109	445.08	12,000
Trading Asset Securities	4,434	4,989	3,186	30,130	20,236
Cash & Short-Term Investments	46,998	30,913	32,075	45,128	50,043
Cash Growth	52.03%	-3.62%	-28.93%	-9.82%	-18.43%
Accounts Receivable	20,924	22,932	19,156	24,878	21,084
Other Receivables	1,070	1,398	1,416	591.23	423.74
Receivables	21,994	24,330	20,572	25,469	21,508
Inventory	42,898	44,447	34,535	30,158	29,770
Prepaid Expenses	401.16	550.65	1,141	831.9	865.31
Other Current Assets	466.83	786.85	1,427	1,394	1,022
Total Current Assets	112,758	101,028	89,749	102,981	103,208
Property, Plant & Equipment	87,377	74,796	73,646	95,097	89,880
Long-Term Investments	60,473	69,556	73,947	77,107	68,066
Goodwill	61.2	-	-	-	-
Other Intangible Assets	4,902	5,109	5,689	2,889	2,998
Long-Term Deferred Tax Assets	2,735	2,410	1,557	-	-
Long-Term Deferred Charges	4,795	3,052	-	-	-
Other Long-Term Assets	48,795	46,622	48,083	32,403	27,822
Total Assets	321,895	302,873	292,971	310,478	291,974
Accounts Payable	4,672	5,018	4,880	5,657	5,751
Accrued Expenses	8,006	7,845	6,801	1,463	1,496
Short-Term Debt	30,000	38,641	15,015	24,085	153.95
Current Portion of Leases	155.74	29.67	276.64	1,350	1,489
Current Income Taxes Payable	1,150	-	4,743	1,877	2,770
Current Unearned Revenue	-	-	-	1.76	-
Other Current Liabilities	25,601	26,895	27,310	15,693	13,705
Total Current Liabilities	69,585	78,428	59,027	50,127	25,364
Long-Term Debt	15,125	-	-	-	-
Long-Term Leases	162.96	6.96	81.08	1,434	2,686
Long-Term Deferred Tax Liabilities	-	-	-	1,045	1,016
Other Long-Term Liabilities	8,149	4,100	5,386	347.25	2,618
Total Liabilities	93,022	82,536	64,494	52,953	31,684
Common Stock	15,684	15,684	15,684	15,684	15,684
Additional Paid-In Capital	35,525	34,100	34,108	34,108	34,219
Retained Earnings	193,615	193,299	198,616	231,800	228,447
Treasury Stock	-23,890	-30,133	-28,916	-28,916	-28,166
Comprehensive Income & Other	7,424	7,110	8,686	4,528	9,637
Total Common Equity	228,357	220,061	228,179	257,204	259,821
Minority Interest	515.64	276.2	298.06	320.83	468.74
Shareholders' Equity	228,873	220,337	228,477	257,525	260,290
Total Liabilities & Equity	321,895	302,873	292,971	310,478	291,974
Total Debt	45,443	38,677	15,373	26,869	4,329
Net Cash (Debt)	1,554	-7,764	16,701	18,259	45,714
Net Cash Growth	-	-	-8.53%	-60.06%	-23.28%
Net Cash Per Share	57.41	-288.15	615.52	671.07	1660.97
Filing Date Shares Outstanding	27.13	26.94	27.13	27.13	27.23
Total Common Shares Outstanding	27.13	26.94	27.13	27.13	27.23
Working Capital	43,172	22,599	30,722	52,854	77,844
Book Value Per Share	8417.87	8168.01	8409.41	9479.11	9540.40
Tangible Book Value	223,394	214,952	222,490	254,315	256,823
Tangible Book Value Per Share	8234.92	7978.39	8199.75	9372.64	9430.31
Land	16,599	17,894	17,847	26,002	17,372
Buildings	68,951	70,141	67,935	78,165	58,125
Machinery	68,253	65,901	60,966	60,360	66,259
Construction In Progress	14,723	3,260	4,438	2,565	21,513

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.